Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.18
-0.0700-5.60%
Post-market: 1.180.0007+0.06%19:56 EDT
Volume:804.57K
Turnover:962.91K
Market Cap:19.54M
PE:-2.06
High:1.26
Open:1.26
Low:1.11
Close:1.25
Loading ...

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

ACCESSWIRE
·
28 Oct 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

Market Exclusive
·
28 Oct 2024

MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments

TIPRANKS
·
21 Oct 2024

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

ACCESSWIRE
·
21 Oct 2024

Mira Pharmaceuticals Inc - Reports Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments in Preclinical Study

THOMSON REUTERS
·
21 Oct 2024

Mira Pharmaceuticals - Remains on Track to Submit Ind Application by End of 2024, With Phase I Clinical Trials Expected to Begin in Q1 2025

THOMSON REUTERS
·
21 Oct 2024

MIRA Continues to Post Outstanding Test Results

Zacks Small Cap Research
·
21 Oct 2024

Mira Pharmaceuticals initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
30 Sep 2024

BRIEF-Mira Pharmaceuticals May Offer,Sell Shares Of Common Stock Of Up To $75 Million From Time To Time

Reuters
·
28 Sep 2024

MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models

MT Newswires Live
·
27 Sep 2024

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

ACCESSWIRE
·
27 Sep 2024

MIRA Makes Impressive Progress

Zacks Small Cap Research
·
18 Sep 2024

Mira Pharmaceuticals: Advances Ketamir-2 Development, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

THOMSON REUTERS
·
18 Sep 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

ACCESSWIRE
·
18 Sep 2024